Evidence map›Paper›PMID 42177197›Full record

ArticleNPJ breast cancer2026

WISDOM randomized trial comparing risk-based versus annual breast cancer screening: study cohort characteristics and design.

Allison Fiscalini, Kelly Blum, Kirkpatrick Fergus, Robert A Hiatt, Arash Naeim, Andrea Kaster, Maren T Scheuner, Laura J van 't Veer, Andrea Z LaCroix, Alexander D Borowsky and 33 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02620852 (Enabling a Paradigm Shift), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02620852 narecruitingnot on this map

Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer (Wisdom Study)

TypeinterventionalSponsorUniversity of California, San FranciscoRan2016 to 2026Enrolled100,000ConditionsBreast Cancer Screening, Breast Carcinoma in Situ, Breast CancerArmsComplete a health questionnaire, Provide a saliva sample for genetic testing, Screening advice based on a comprehensive risk assessment, Screening advice based on a basic risk assessment
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

43 authors.

Allison FiscaliniUniversity of California, San Francisco, San Francisco, CA, USA. Allison.stoverfiscalini@ucsf.edu.ORCID http://orcid.org/0000-0002-9639-4053
Kelly BlumUniversity of California, San Francisco, San Francisco, CA, USA.
Kirkpatrick FergusUniversity of California, San Francisco, San Francisco, CA, USA.
Robert A HiattUniversity of California, San Francisco, San Francisco, CA, USA.
Arash NaeimUniversity of California Los Angeles, Los Angeles, CA, USA.
Andrea KasterSanford Health, Fargo, ND, USA.
Maren T ScheunerUniversity of California, San Francisco, San Francisco, CA, USA.
Laura J van 't VeerUniversity of California, San Francisco, San Francisco, CA, USA.
Andrea Z LaCroixUniversity of California San Diego, San Diego, USA.
Alexander D BorowskyUniversity of California, San Francisco, San Francisco, CA, USA.
Olufunmilayo I OlopadeUniversity of Chicago, Chicago, IL, USA.
Hannah L ParkUniversity of California Irvine, Irvine, CA, USA.
James EssermanDiagnostic Center of Miami, Miami, FL, USA.
Rachael LancasterUniversity of Alabama at Birmingham, Birmingham, USA.
Diane HeditsianUniversity of California, San Francisco, San Francisco, CA, USA.
Susie BrainUniversity of California, San Francisco, San Francisco, CA, USA.
Vivian LeeUniversity of California, San Francisco, San Francisco, CA, USA.
Deborah L GoodmanUniversity of California Irvine, Irvine, CA, USA.
Katherine S RossUniversity of California, San Francisco, San Francisco, CA, USA.
Neil WengerUniversity of California Los Angeles, Los Angeles, CA, USA.
Barbara A ParkerUniversity of California San Diego, San Diego, USA.
Lisa MadlenskyUniversity of California San Diego, San Diego, USA.
Jeffrey A TiceUniversity of California, San Francisco, San Francisco, CA, USA.
Yiwey ShiehWeill Cornell Medicine, New York, NY, USA.
Elad ZivUniversity of California, San Francisco, San Francisco, CA, USA.
Vignesh A ArasuKaiser Permanente Northern California Division of Research, Pleasanton, CA, USA.
Hoda Anton-CulverUniversity of California Irvine, Irvine, CA, USA.
Celia P KaplanUniversity of California, San Francisco, San Francisco, CA, USA.
Kim F RhoadsUniversity of California, San Francisco, San Francisco, CA, USA.
Kimberly BadalUniversity of California, San Francisco, San Francisco, CA, USA.
Michael HogarthUniversity of California San Diego, San Diego, USA.
Antonia PetruseUniversity of California Los Angeles, Los Angeles, CA, USA.
Irene A SotoUniversity of California, San Francisco, San Francisco, CA, USA.
Katherine Leggat-BarrUniversity of California, San Francisco, San Francisco, CA, USA.
Steffanie GoodmanUniversity of California, San Francisco, San Francisco, CA, USA.
Jennifer AtamerUniversity of California, San Francisco, San Francisco, CA, USA.
Rita RyuUniversity of California San Diego, San Diego, USA.
Kelly AdduciUniversity of California, San Francisco, San Francisco, CA, USA.
Jeffrey B MatthewsUniversity of California, San Francisco, San Francisco, CA, USA.
Martin EklundKarolinska Institutet, Stockholm, Sweden.
Athena/WISDOM Network Collaborators and Advocate Partners
Leah P SabacanUniversity of California, San Francisco, San Francisco, CA, USA.
Laura EssermanUniversity of California, San Francisco, San Francisco, CA, USA. laura.esserman@ucsf.edu.ORCID http://orcid.org/0000-0001-9202-4568

Funding

Extending the Diversity, Reach, and Generalizability of the WISDOM StudyR01CA237533 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ESSERMAN, LAURA J · 2020 to 2024
$9.1M
Breast Cancer Research Foundation SPEC-18-006, SPEC-22-018, SPEC-24-026NCI NIH HHS R01 CA237533NCI NIH HHS R01CA237533Patient Centered Outcomes Institute PCS-1402-10749Robert Wood Johnson Foundation Pioneer Pitch Award 71864
6 · The paper itself

Abstract

The Women Informed to Screen Depending on Measures of risk (WISDOM) Study (clinicaltrials.gov NCT02620852, 2016-08-31) is pragmatic randomized controlled trial evaluating risk assessment to inform the age to start, frequency and modality of breast cancer screening and risk reduction. The WISDOM Study uses a preference-tolerant design, enabling women who decline randomization to self-select their screening arm. The risk-based arm included comprehensive breast cancer risk assessment using the Breast Cancer Surveillance Consortium (BCSC) model and genetics. From August 2016 to February 2023, WISDOM enrolled a large, diverse, nationwide cohort of 46,403 participants - 77% non-Hispanic (NH) White, 9% Hispanic, 6% (NH) Black, and 5% (NH) Asian; demographic diversity increased over time. Mean age at baseline was 54 years. 28,372 (61%) were randomized, while 89% of those who self-selected their screening arm chose risk-based screening. The preference-tolerant design captured real-world screening preferences while maintaining scientific rigor and demonstrated strong preference for risk-based screening.

Identifiers

PMID42177197
PMCPMC13478457

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.